EKF Diagnostics Holdings PLC Posting of Annual Report & Accounts &Notice of AGM (1031J)
25 4월 2022 - 3:00PM
UK Regulatory
TIDMEKF
RNS Number : 1031J
EKF Diagnostics Holdings PLC
25 April 2022
EKF Diagnostics Holdings plc
("EKF" or the "Company")
Posting of Annual Report & Accounts
and
Notice of Annual General Meeting
EKF (AIM: EKF) , the AIM-listed global diagnostics business, c
onfirms that the Annual Report and Accounts for the year ended 31
December 2021 ("2021 Annual Report") and the Notice of the 2022
Annual General Meeting ("AGM") have now been published on the
Company's website here .
The 2021 Annual Report, the Notice of AGM and details for voting
by proxy will be posted to shareholders who have not consented to
receive electronic communications today, on 25 April 2022.
The AGM is to be held at 11:00 am on 18 May 2022 at 6 Stratton
Street Mayfair, London W1J 8LD and will consider the Resolutions
set out in the Notice of AGM.
The Company is providing a facility for shareholders to listen
in to the AGM either online or telephonically (in a non-voting
capacity) and there will be an opportunity for shareholders to ask
questions. In order to facilitate the process, the Directors would
request that shareholders register for the meeting and submit
questions in advance, before 11:00 am on 17 May 2022. To register
for dial-in details and to submit any questions please contact
Walbrook PR via email at ekf@walbrookpr.com or call +44 (0)20 7933
8787.
Proxy voting
Shareholders will not receive a hard copy form of proxy for the
2022 AGM in the post. Instead, Shareholders will be able to vote
electronically using the link www.signalshares.com . Proxy votes
must be received no later than 11:00 am on 16 May 2022.
Shareholders may request a hard copy form of proxy directly from
the Registrars, Link Group, on Tel: 0371 664 0300. Calls are
charged at the standard geographic rate and will vary by provider.
Calls outside the United Kingdom will be charged at the applicable
international rate. Lines are open between 09:00 - 17:30, Monday to
Friday excluding public holidays in England and Wales.
EKF Diagnostics Holdings plc www.ekfdiagnostics.com
Mike Salter, CEO Tel: +44 (0)29 2071 0570
Marc Davies, CFO
Singer Capital Markets (Nominated Adviser & Tel: +44 (0)20 7496 3000
Joint Broker)
Aubrey Powell / George Tzimas / Tom
Salvesen
Investec Bank plc (Joint Broker) Tel: +44 (0)20 7597 4000
Gary Clarence / Daniel Adams / Ben
Farrow
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com
Paul McManus / Lianne Applegarth Mob: +44 (0)7980 541 893 / +44 (0)7584
391 303
About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com
)
EKF is a leading global diagnostics business with custom
manufacturing facilities across sites in the US, UK and Europe for
a variety of life science products. EKF is focussed on the
following areas:
Point-of-Care Providing a portfolio of Point-of-Care analysers and
consumables, particularly for use in the area of Hematology
and Diabetes, for use in hospital and research laboratories,
doctor's offices, blood banks and for in-field anaemia
screening programmes. EKF has an estimated 80,000
hemoglobin, hematocrit, HbA1c, glucose and lactate
analysers in regular use across more than 100 countries.
Central Laboratory Clinical chemistry, Small lab analysers, Centrifuges
Beta-Hydroxybutyrate (<BETA>-HB) LiquiColor , Glycated
Albumin, Glycated Serum Protein, Nitro-tab, Procalcitonin
Life Sciences Enzyme fermentation, Custom products and Bulk fermentation
Contract Manufacturing Bulk formulation, Sample collection kits, Private
labelling, Molecular and forensic kits
Laboratory Services In September 2021, EKF completed the acquisition of
Advanced Diagnostic Laboratory LLC ("ADL Health")
, a Texas based testing laboratory certified under
the Clinical Laboratory Improvement Amendments ("CLIA")
for high complexity testing. The laboratory provides
testing for a variety of clinical, forensic and microbiological
sample types using a range of analytical techniques.
This acquisition positions EKF as a leading 'one stop'
provider of diagnostic products and services from
sample collection to results.
In May 2021, EKF announced its strategy for delivering growth to
2024 and beyond, and continuing to deliver shareholder value. The
strategy for growth can be summarised as:
-- continuing innovation in products and services in Point-of-Care,
Central Laboratory and Life Sciences leveraging new and existing
routes to market and relationships;
-- investment in expanded production and kitting capabilities to offer
a suite of diagnostic Contract Manufacturing solutions to third
party businesses;
-- expansion of CLIA Laboratories Testing offering, building on the
acquired capabilities in ADL Health; and
-- identify complementary earnings-enhancing acquisitions with key
strategic value.
EKF will also continue to generate enhanced shareholder value
through:
-- a progressive dividend policy; and
-- its agreement with Mount Sinai Innovation Partners ("MSIP"), which
allows us advanced access to innovative commercial opportunities
and where we can build on the ongoing successes of Renalytix plc,
Verici Dx plc and Trellus Health plc.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ACSITMITMTATBPT
(END) Dow Jones Newswires
April 25, 2022 02:00 ET (06:00 GMT)
EKF Diagnostics (AQSE:EKF.GB)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
EKF Diagnostics (AQSE:EKF.GB)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
